Capital L.l.c. FirstMark files SEC Form 4 disclosures for MAP Pharmaceuticals, Inc.. They have made 16 open-market trades across 3 companies since 2008, most recently 2009-11-10.
CIK 0001437638
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $42K since 2009, against 15 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MAPP | SELL | 2009-07-14 | 2009-07-16 | $10.56 | $102K | N/A | N/A | N/A |
| MAPP | SELL | 2009-07-02 | 2009-07-06 | $12.00 | $29K | N/A | N/A | N/A |
| MAPP | SELL | 2009-07-01 | 2009-07-02 | $12.09 | $544K | N/A | N/A | N/A |
| MAPP | SELL | 2009-06-26 | 2009-06-29 | $11.36 | $491K | N/A | N/A | N/A |
| MAPP | SELL | 2009-06-26 | 2009-06-29 | $11.10 | $982K | N/A | N/A | N/A |
| MAPP | SELL | 2009-06-23 | 2009-06-24 | $11.11 | $809K | N/A | N/A | N/A |
| MAPP | SELL | 2009-06-23 | 2009-06-25 | $11.17 | $62K | N/A | N/A | N/A |
| MAPP | BUY | 2009-06-19 | 2009-06-23 | $11.32 | $6K | N/A | N/A | N/A |
| MAPP | SELL | 2009-06-19 | 2009-06-23 | $11.10 | $411K | N/A | N/A | N/A |
| MAPP | SELL | 2009-06-19 | 2009-06-23 | $11.50 | $16K | N/A | N/A | N/A |
| MAPP | SELL | 2009-05-28 | 2009-05-29 | $13.50 | $138K | N/A | N/A | N/A |
| MAPP | SELL | 2009-05-28 | 2009-05-29 | $13.34 | $624K | N/A | N/A | N/A |
| MAPP | SELL | 2009-05-28 | 2009-05-29 | $13.20 | $828K | N/A | N/A | N/A |
| MAPP | SELL | 2009-05-28 | 2009-05-29 | $13.12 | $596K | N/A | N/A | N/A |
| MAPP | SELL | 2009-05-27 | 2009-05-29 | $12.96 | $1.1M | N/A | N/A | N/A |
| SABA | BUY | 2009-01-26 | 2009-01-28 | $1.50 | $36K | -2.7% | +0.2% | +0.2% |
| FADV | SELL | 2008-12-12 | 2008-12-15 | $15.10 | $196K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.